Specifically, we used CAR-T cells that we have developed for targeting the protein STEAP1 (six-transmembrane epithelial antigen of prostate-1), which is expressed in most prostate cancers and Ewing sarcomas, as well as in subgroups of other cancers [12]. This evidence concerns the gene STEAP1 and prostate cancer.